

## **Product** Data Sheet

## $\hbox{1,2-Dimyristoyl-sn-glycero-3-phosphocholine-d}_{13}$


 $\begin{array}{lll} \textbf{Cat. No.:} & \text{HY-109541S3} \\ \textbf{CAS No.:} & 326495\text{-}28\text{-}7 \\ \textbf{Molecular Formula:} & \textbf{C}_{36}\textbf{H}_{59}\textbf{D}_{13}\textbf{NO}_{8}\textbf{P} \\ \end{array}$ 

Molecular Weight: 691.01

Target: Liposome; Isotope-Labeled Compounds
Pathway: Metabolic Enzyme/Protease; Others

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

Description	$1,2$ -Dimyristoyl-sn-glycero- $3$ -phosphocholine- $d_{13}$ is deuterium labeled $1,2$ -Dimyristoyl-sn-glycero- $3$ -phosphocholine (DMPC) is a synthetic phospholipid used in liposomes. $1,2$ -Dimyristoyl-sn-glycero- $3$ -phosphocholine
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Iwona Budziak, et al. Effect of polyols on the DMPC lipid monolayers and bilayers. Biochim Biophys Acta Biomembr. 2018 Nov;1860(11):2166-2174.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1

Inhibitors